Palvella Therapeutics, Inc. (PVLA) Net Cash Flow (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Net Cash Flow for 12 consecutive years, with $69.4 million as the latest value for Q4 2024.
- On a quarterly basis, Net Cash Flow rose 661.73% to $69.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $87.6 million, a 2555.56% increase, with the full-year FY2024 number at $76.3 million, up 2212.49% from a year prior.
- Net Cash Flow was $69.4 million for Q4 2024 at Palvella Therapeutics, up from -$188000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $69.4 million in Q4 2024 to a low of -$33.0 million in Q1 2022.
- A 5-year average of $3.5 million and a median of $359500.0 in 2023 define the central range for Net Cash Flow.
- Peak YoY movement for Net Cash Flow: surged 1488.58% in 2021, then plummeted 1235.75% in 2022.
- Palvella Therapeutics' Net Cash Flow stood at $1.5 million in 2020, then tumbled by 523.13% to -$6.4 million in 2021, then tumbled by 83.76% to -$11.7 million in 2022, then soared by 177.69% to $9.1 million in 2023, then surged by 661.73% to $69.4 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Net Cash Flow are $69.4 million (Q4 2024), -$188000.0 (Q3 2024), and $10.5 million (Q2 2024).